Unveiling 6 Analyst Insights On Capricor Therapeutics
Analysts' ratings for Capricor Therapeutics (NASDAQ:CAPR) over the last quarter vary from bullish to bearish, as provided by 6 analysts.The table below provides a concise overview of recent ratings by
HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $40 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Buy and maintains $40 price target.
Capricor Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/02/2024 726.45% HC Wainwright & Co. $40 → $40 Reiterates Buy → Buy 05/17/2024 189.26% Oppenheimer → $14
H.C. Wainwright Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $40
H.C. Wainwright analyst Joseph Pantginis maintains $Capricor Therapeutics(CAPR.US)$ with a buy rating, and maintains the target price at $40.According to TipRanks data, the analyst has a success rate
Capricor Therapeutics' CAP-1002 Shows Promise in DMD Treatment: Buy Rating Affirmed Following Positive Clinical Trials
Capricor Therapeutics Set to Join Russell 2000 and Russell 3000 Indexes
SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today
Capricor Therapeutics (CAPR) Gets a Buy From Oppenheimer
What's Going On With Capricor Therapeutics Stock Friday?
Capricor Therapeutics, Inc. (NASDAQ:CAPR) shares are trading higher on Friday. The company announced the long-term benefits of deramiocel for the treatment of duchenne muscular dystrophy (DMD).What Ha
Capricor Therapeutics Rises on Muscular Dystrophy Treatment Study
By Victor Swezey Shares of Capricor Therapeutics climbed after a study showed positive safety and efficacy results for its muscular dystrophy treatment. The stock jumped 6.3% in morning trading Frid
Express News | Capricor Therapeutics Inc: Pre-Bla Meeting With FDA Scheduled for Q3 2024 to Discuss Options to Expedite Bla Filing
Express News | Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (Cap-1002) in Both Skeletal Muscle and Cardiac Function in the Hope-2 Ole Study in Duchenne Muscular Dystrophy
Express News | Corrected(Official)-Capricor Therapeutics Announces Pre-Bla Meeting With FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy (Adds Dropped Words 'pre-Bla Meeting With FDA for Deramiocel')
CORRECTION: Capricor Therapeutics
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- In a release issued under the headline "Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy" on Tuesday, June 25th by Capric
Express News | Capricor Therapeutics Inc: FDA Scheduled Pre-Bla Meeting in Q3 for Deramiocel (Cap-1002)
Express News | Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy
Oppenheimer Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $14
Oppenheimer analyst Leland Gershell maintains $Capricor Therapeutics(CAPR.US)$ with a buy rating, and maintains the target price at $14.According to TipRanks data, the analyst has a success rate of 34
Capricor Therapeutics Files for $150M Mixed Shelf
Express News | Capricor Therapeutics Inc Files for Mixed Shelf Offering of up to $150 Mln- SEC Filing
Sector Update: Health Care Stocks Decline Tuesday Afternoon
Health care stocks were lower Tuesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each shedding about 0.6%. The iShares Biotechnology ETF (IBB) fell ab
Capricor Says FDA Grants Pre-BLA Meeting Request for Duchenne Muscular Dystrophy Treatment; Shares Rise
Capricor Therapeutics (CAPR) said Tuesday the US Food and Drug Administration has agreed to a pre-biologics license application meeting regarding the company's lead CAP-1002 treatment candidate for Du